mipomersen sodium + placebo
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Heterozygous Familial Hypercholesterolemia
Conditions
Heterozygous Familial Hypercholesterolemia, Coronary Artery Disease
Trial Timeline
Jul 1, 2008 → May 1, 2010
NCT ID
NCT00706849About mipomersen sodium + placebo
mipomersen sodium + placebo is a phase 3 stage product being developed by Ionis Pharmaceuticals for Heterozygous Familial Hypercholesterolemia. The current trial status is completed. This product is registered under clinical trial identifier NCT00706849. Target conditions include Heterozygous Familial Hypercholesterolemia, Coronary Artery Disease.
What happened to similar drugs?
1 of 14 similar drugs in Heterozygous Familial Hypercholesterolemia were approved
Approved (1) Terminated (1) Active (13)
Hype Score Breakdown
Clinical
17
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00770146 | Phase 3 | Completed |
| NCT00706849 | Phase 3 | Completed |
Competing Products
18 competing products in Heterozygous Familial Hypercholesterolemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AZD0780 + Placebo | AstraZeneca | Phase 3 | 44 |
| Anacetrapib + Placebo for anacetrapib | Merck | Phase 3 | 40 |
| Enlicitide Decanoate + Placebo | Merck | Phase 2/3 | 45 |
| Inclisiran | Novartis | Phase 3 | 44 |
| Inclisiran + Placebo | Novartis | Phase 3 | 40 |
| Fluvastatin | Novartis | Phase 3 | 40 |
| Inclisiran + Placebo | Novartis | Phase 3 | 47 |
| Evolocumab + Placebo | Amgen | Phase 3 | 40 |
| Bococizumab (PF-04950615;RN316) | Pfizer | Phase 3 | 40 |
| Atorvastatin + Atorvastatin | Pfizer | Phase 1 | 29 |
| IBI306 + placebo | Innovent Biologics | Phase 3 | 40 |
| Lumacaftor Plus Ivacaftor Combination + Ivacaftor | Vertex Pharmaceuticals | Phase 3 | 40 |
| LMT (atorvastatin, simvastatin, or rosuvastatin) + alirocumab + Placebo | Sanofi | Phase 3 | 40 |
| Placebo + Alirocumab | Sanofi | Phase 3 | 40 |
| Praluent | Sanofi | Approved | 35 |
| AK102 + Placebo + Statins and/or Ezetimibe | Akeso | Phase 2 | 35 |
| lerodalcibep | Medpace | Phase 3 | 37 |
| MGL-3196 (resmetirom) + Placebo | Madrigal Pharmaceuticals | Phase 2 | 32 |